Lataa...
Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor signaling pathway that favors the stimulation of bone formation. Here, we report a prospective, exploratory analysis of bone mineral density (BMD) response rates comparing sequential abaloparatide/alendronate vs placeb...
Tallennettuna:
| Julkaisussa: | Bone Rep |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6883300/ https://ncbi.nlm.nih.gov/pubmed/31799340 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bonr.2019.100230 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|